Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P05412 (
c-Jun
)
11,453
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
In previous studies it has been shown that neural cells undergoing programmed cell death display strongly positive cytoplasmic immunoreactivity to polyclonal antibodies directed against a
c-Jun
N-terminal peptide. It was later found that
c-Jun
-like immunoreactivity in apoptosis was due to cross-reactivity with proteins other than c-JUN: We have analysed the biochemical counterpart of this property in neuroblastoma cell lines treated to induce apoptosis. Using the
c-Jun
/sc-45 antibody, several bands with apparent molecular masses distinct from
c-Jun
were detected in extracts in parallel with both the degree of apoptosis and the appearance of the cytoplasmic signal after immunostaining.
c-Jun
/sc-45 immunostaining was prevented by caspase inhibitors and did not require de novo protein synthesis. One of the antigens recognized by the
c-Jun
/sc-45 antibody was identified as
seryl-tRNA synthetase
. We provide evidence that
seryl-tRNA synthetase
is a substrate of caspase-3 in vitro and that the digested form turns highly immunoreactive towards the antibody. A carboxy-terminus epitope of the protein that constitutes a consensus site for caspase-3 is involved in
c-Jun
/sc-45 recognition. This epitope shares some amino acids with the peptide used as the immunogen and this could explain the cross-reactivity observed. In conclusion, we demonstrate here that cytoplasmic
c-Jun
/sc-45-like immunoreactivity specific to apoptosis is due to post-translational changes which occur in
seryl-tRNA synthetase
and probably also in other proteins as a consequence of caspase mediated proteolysis.
...
PMID:Antibodies against c-Jun N-terminal peptide cross-react with neo-epitopes emerging after caspase-mediated proteolysis during apoptosis. 1133 19